236 related articles for article (PubMed ID: 18195120)
1. Economic burden and the cost-effectiveness of treatment of cardiovascular diseases in Africa.
Gaziano TA
Heart; 2008 Feb; 94(2):140-4. PubMed ID: 18195120
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level.
Gaziano TA; Steyn K; Cohen DJ; Weinstein MC; Opie LH
Circulation; 2005 Dec; 112(23):3569-76. PubMed ID: 16330698
[TBL] [Abstract][Full Text] [Related]
4. The economic costs of cardiovascular disease mortality in California, 1991: implications for public health policy.
Fox P; Gazzaniga J; Karter A; Max W
J Public Health Policy; 1996; 17(4):442-59. PubMed ID: 9009539
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of interventions to reduce dietary salt intake.
Cobiac LJ; Vos T; Veerman JL
Heart; 2010 Dec; 96(23):1920-5. PubMed ID: 21041840
[TBL] [Abstract][Full Text] [Related]
6. An overview of cardiovascular disease burden in the United States.
Mensah GA; Brown DW
Health Aff (Millwood); 2007; 26(1):38-48. PubMed ID: 17211012
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of community-based physical activity interventions.
Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
[TBL] [Abstract][Full Text] [Related]
8. Salt and high blood pressure.
Mohan S; Campbell NR
Clin Sci (Lond); 2009 Jun; 117(1):1-11. PubMed ID: 19476440
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of physical inactivity: healthcare costs associated with cardiovascular disease.
Oldridge NB
Eur J Cardiovasc Prev Rehabil; 2008 Apr; 15(2):130-9. PubMed ID: 18391637
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness research on preventive interventions: a survey of the publications in 2008.
van Gils PF; Tariq L; Verschuuren M; van den Berg M
Eur J Public Health; 2011 Apr; 21(2):260-4. PubMed ID: 20534690
[TBL] [Abstract][Full Text] [Related]
11. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
Palmer AJ; Valentine WJ; Chen R; Mehin N; Gabriel S; Bregman B; Rodby RA
Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of chronic cardiovascular disease for major insurers.
Trogdon JG; Finkelstein EA; Nwaise IA; Tangka FK; Orenstein D
Health Promot Pract; 2007 Jul; 8(3):234-42. PubMed ID: 17606951
[TBL] [Abstract][Full Text] [Related]
13. Improving cardiovascular disease prevention and management in Africa: issues to consider for the 21st century.
Madu EC; Richardson KD; Ozigbo OH; Baugh DS
Ethn Dis; 2003; 13(2 Suppl 2):S71-6. PubMed ID: 13677417
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
15. Economics of psychosocial factors in patients with cardiovascular disease.
Rodwin BA; Spruill TM; Ladapo JA
Prog Cardiovasc Dis; 2013; 55(6):563-73. PubMed ID: 23621966
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of cardiovascular diseases in the enlarged European Union.
Leal J; Luengo-Fernández R; Gray A; Petersen S; Rayner M
Eur Heart J; 2006 Jul; 27(13):1610-9. PubMed ID: 16495286
[TBL] [Abstract][Full Text] [Related]
17. The impact of prevention on reducing the burden of cardiovascular disease.
Kahn R; Robertson RM; Smith R; Eddy D
Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
[TBL] [Abstract][Full Text] [Related]
18. The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.
Muszbek N; Brixner D; Benedict A; Keskinaslan A; Khan ZM
Int J Clin Pract; 2008 Feb; 62(2):338-51. PubMed ID: 18199282
[TBL] [Abstract][Full Text] [Related]
19. The medical cost of cardiometabolic risk factor clusters in the United States.
Sullivan PW; Ghushchyan V; Wyatt HR; Hill JO
Obesity (Silver Spring); 2007 Dec; 15(12):3150-8. PubMed ID: 18198326
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
Greving JP; Buskens E; Koffijberg H; Algra A
Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
